NextGen Sciences to Develop and Validate Protein Biomarker Assays for Takeda Pharmaceuticals
News Feb 02, 2010
The biomarker assays will be designed to target specific protein isoforms found in liver and muscle in multiple species, for use in preclinical studies, and will also be validated for use in clinical studies. NextGen Sciences’ Multiple Reaction Monitoring (MRM) protein assay platform is ideal for studies of this kind, which involve multiple isoforms and multiple species.
Dr Michael Pisano, CEO of NextGen Sciences, commented: “We are delighted to have been chosen for this project and look forward to working closely with Takeda’s scientists in Japan.”
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE